|Mr. Herman Verrelst||CEO & Exec. Director||468.75k||N/A||1974|
|Mr. Jean-Marc Roelandt||Chief Financial Officer||N/A||N/A||1965|
|Mr. Piet Houwen||Chief Operating Officer||N/A||N/A||1968|
|Mr. Benoit Devogelaere||Chief Technology Officer||N/A||N/A||1981|
|Mr. Geert Maertens||Chairman of Scientific Advisory Board & Chief Scientific Officer||N/A||N/A||N/A|
|Renate Degrave||Head of IR & Corp. Communications||N/A||N/A||N/A|
|Ms. Susy Spruyt||Head of People & Organization||N/A||N/A||1968|
|Dr. Erwin Sablon||Head of R&D and Alliance Management||N/A||N/A||1965|
|Mr. Reginald Van Genechten||Head of Manufacturing & Supply Chain||N/A||N/A||1966|
|Mr. Dirk Zimmermann||Global Head of Pharma Collaborations & Partnering||N/A||N/A||N/A|
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers formalin fixed, paraffin embedded solid biopsy tests, including diagnostic products, such as Idylla BRAF, KRAS, NRAS-BRAF, NRAS, and EGFR mutation tests; and research products, which include Idylla MSI and NRAS-BRAF-EGFR S492R mutation assays. It also provides plasma liquid biopsy tests comprising diagnostic products that include Idylla ctKRAS and ctNRAS-BRAF mutation tests; and research products consisting of Idylla ctBRAF and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with AstraZeneca to develop and commercialize Idylla based molecular tests in support of AstraZeneca's pharmaceutical products; Bristol-Myers Squibb Company for the registration of Idylla MSI Test as companion diagnostic test for metastatic colorectal cancer in China; and Endpoint Health, Inc. for the development and commercialization of a novel companion diagnostic test based on Idylla molecular diagnostics platform. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform. Biocartis Group NV was founded in 2007 and is headquartered in Mechelen, Belgium.
Biocartis Group NV’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.